The DOI matches its Crossref record; 80 of the 80 references it cites were found in a registry or an index.
Investigational nanomedicines in 2016: a review of nanotherapeutics currently undergoing clinical trials
Abstract
Nanomedicine is a relatively new field that is rapidly evolving. Formulation of drugs on the nanoscale imparts many physical and biological advantages. Such advantages can in turn translate into improved therapeutic efficacy and reduced toxicity. While approximately 50 nanotherapeutics have already entered clinical practice, a greater number of drugs are undergoing clinical investigation for a variety of indications. This review aims to examine all the nanoformulations that are currently undergoing clinical investigation and their outlook for ultimate clinical translation. WIREs Nanomed Nanobiotechnol 2017, 9:e1416. doi: 10.1002/wnan.1416 This article is categorized under: Therapeutic Approaches and Drug Discovery > Emerging Technologies
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Laurent, S., Forge, D., Port, M., Roch, A., Robic, C., Vander Elst, L., & Muller, R. N. (2008) · Chemical Reviews · doi:10.1021/cr068445e · Cited by 6,852
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Von Hoff, D. D., Ervin, T., Arena, F. P., Chiorean, E. G., Infante, J., Moore, M., Seay, T., Tjulandin, S. A., Ma, W. W., Saleh, M. N., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1304369 · Cited by 6,712
Liposomal drug delivery systems: From concept to clinical applications
Allen, T. M., & Cullis, P. R. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.09.037 · Cited by 4,839 · cited 1×
“They improve loading of both hydrophobic and hydrophilic drugs.(7) Approved liposomal chemotherapeutics include Doxil and Myocet (doxorubicin), DepoCyte (cytarabine), and DaunoXome (daunorubicin), among several others as reviewed previously.”
BackgroundRegulation of transport pathways in tumor vessels: Role of tumor type and microenvironment
Hobbs, S. K., Monsky, W. L., Yuan, F., Roberts, W. G., Griffith, L., Torchilin, V. P., & Jain, R. K. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.8.4607 · Cited by 2,438
Plasmonic photothermal therapy (PPTT) using gold nanoparticles
Huang, X., Jain, P. K., El-Sayed, I. H., & El-Sayed, M. A. (2008) · Lasers in Medical Science · doi:10.1007/s10103-007-0470-x · Cited by 2,376
Gradishar, W. J., Tjulandin, S., Davidson, N., Shaw, H., Desai, N., Bhar, P., Hawkins, M., & O'Shaughnessy, J. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.937 · Cited by 2,153
Silver Nanoparticles as Potential Antibacterial Agents
Franci, G., Falanga, A., Galdiero, S., Palomba, L., Rai, M., Morelli, G., & Galdiero, M. (2015) · Molecules · doi:10.3390/molecules20058856 · Cited by 1,674
Gelderblom, H., Verweij, J., Nooter, K., & Sparreboom, A. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00171-x · Cited by 1,655
Smart micro/nanoparticles in stimulus-responsive drug/gene delivery systems
Karimi, M., Ghasemi, A., Sahandi Zangabad, P., Rahighi, R., Moosavi Basri, S. M., Mirshekari, H., Amiri, M., Shafaei Pishabad, Z., Aslani, A., Bozorgomid, M., et al. (2016) · Chemical Society Reviews · doi:10.1039/c5cs00798d · Cited by 1,519
Maier-Hauff, K., Ulrich, F., Nestler, D., Niehoff, H., Wust, P., Thiesen, B., Orawa, H., Budach, V., & Jordan, A. (2011) · Journal of Neuro-Oncology · doi:10.1007/s11060-010-0389-0 · Cited by 1,429
Colloidal Gold: A Novel Nanoparticle Vector for Tumor Directed Drug Delivery
Paciotti, G. F., Myer, L., Weinreich, D., Goia, D., Pavel, N., McLaughlin, R. E., & Tamarkin, L. (2004) · Drug Delivery · doi:10.1080/10717540490433895 · Cited by 1,185
Hrkach, J., Von Hoff, D., Ali, M. M., Andrianova, E., Auer, J., Campbell, T., De Witt, D., Figa, M., Figueiredo, M., Horhota, A., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003651 · Cited by 1,147
Safety and efficacy of RNAi therapy for transthyretin amyloidosis
Coelho, T., Adams, D., Silva, A., Lozeron, P., Hawkins, P. N., Mant, T., Perez, J., Chiesa, J., Warrington, S., Tranter, E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1208760 · Cited by 971
Kim, T.-Y., Kim, D.-W., Chung, J.-Y., Shin, S. G., Kim, S.-C., Heo, D. S., Kim, N. K., & Bang, Y.-J. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0655 · Cited by 821
Clinical Translation of Nanomedicine
Min, Y., Caster, J. M., Eblan, M. J., & Wang, A. Z. (2015) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00116 · Cited by 772
Self-citationPhase I and Pharmacokinetic Studies of CYT-6091, a Novel PEGylated Colloidal Gold-rhTNF Nanomedicine
Libutti, S. K., Paciotti, G. F., Byrnes, A. A., Alexander, H. R., Gannon, W. E., Walker, M., Seidel, G. D., Yuldasheva, N., & Tamarkin, L. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0978 · Cited by 710
Tabernero, J., Shapiro, G. I., LoRusso, P. M., Cervantes, A., Schwartz, G. K., Weiss, G. J., Paz-Ares, L., Cho, D. C., Infante, J. R., Alsina, M., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0429 · Cited by 698
Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin
Matsumura, Y., Hamaguchi, T., Ura, T., Muro, K., Yamada, Y., Shimada, Y., Shirao, K., Okusaka, T., Ueno, H., Ikeda, M., et al. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6602204 · Cited by 623
Fitzgerald, K., Frank-Kamenetsky, M., Shulga-Morskaya, S., Liebow, A., Bettencourt, B. R., Sutherland, J. E., Hutabarat, R. M., Clausen, V. A., Karsten, V., Cehelsky, J., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)61914-5 · Cited by 577
Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis
Caminero, J. A., Sotgiu, G., Zumla, A., & Migliori, G. B. (2010) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(10)70139-0 · Cited by 574
Hamaguchi, T., Matsumura, Y., Suzuki, M., Shimizu, K., Goda, R., Nakamura, I., Nakatomi, I., Yokoyama, M., Kataoka, K., & Kakizoe, T. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602479 · Cited by 565
Emerging concepts in dendrimer‐based nanomedicine: from design principles to clinical applications
Kannan, R. M., Nance, E., Kannan, S., & Tomalia, D. A. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12280 · Cited by 542
Lee, K. S., Chung, H. C., Im, S. A., Park, Y. H., Kim, C. S., Kim, S.-B., Rha, S. Y., Lee, M. Y., & Ro, J. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9591-y · Cited by 541
Current progress of siRNA/shRNA therapeutics in clinical trials
Burnett, J. C., Rossi, J. J., & Tiemann, K. (2011) · Biotechnology Journal · doi:10.1002/biot.201100054 · Cited by 444
Zuckerman, J. E., Gritli, I., Tolcher, A., Heidel, J. D., Lim, D., Morgan, R., Chmielowski, B., Ribas, A., Davis, M. E., & Yen, Y. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1411393111 · Cited by 427
Lipid Formulations of Amphotericin B: Recent Progress and Future Directions
Hiemenz, J. W., & Walsh, T. J. (1996) · Clinical Infectious Diseases · doi:10.1093/clinids/22.supplement_2.s133 · Cited by 404
Plummer, R., Wilson, R. H., Calvert, H., Boddy, A. V., Griffin, M., Sludden, J., Tilby, M. J., Eatock, M., Pearson, D. G., Ottley, C. J., et al. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.6 · Cited by 390
Johannsen, M., Gneveckow, U., Taymoorian, K., Thiesen, B., Waldöfner, N., Scholz, R., Jung, K., Jordan, A., Wust, P., & Loening, S. A. (2007) · International Journal of Hyperthermia · doi:10.1080/02656730601175479 · Cited by 382
Nanoscale Radiotherapy with Hafnium Oxide Nanoparticles
Maggiorella, L., Barouch, G., Devaux, C., Pottier, A., Deutsch, E., Bourhis, J., Borghi, E., & Levy, L. (2012) · Future Oncology · doi:10.2217/fon.12.96 · Cited by 373
Kim, D.-W., Kim, S.-Y., Kim, H.-K., Kim, S.-W., Shin, S. W., Kim, J. S., Park, K., Lee, M. Y., & Heo, D. S. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm374 · Cited by 356
Meers, P., Neville, M., Malinin, V., Scotto, A. W., Sardaryan, G., Kurumunda, R., Mackinson, C., James, G., Fisher, S., & Perkins, W. R. (2008) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkn059 · Cited by 345
Lancet, J. E., Cortes, J. E., Hogge, D. E., Tallman, M. S., Kovacsovics, T. J., Damon, L. E., Komrokji, R., Solomon, S. R., Kolitz, J. E., Cooper, M., et al. (2014) · Blood · doi:10.1182/blood-2013-12-540971 · Cited by 339
Golan, T., Khvalevsky, E. Z., Hubert, A., Gabai, R. M., Hen, N., Segal, A., Domb, A., Harari, G., David, E. B., Raskin, S., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4183 · Cited by 336
Mignani, S., El Kazzouli, S., Bousmina, M., & Majoral, J.-P. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.01.001 · Cited by 335
Valle, J. W., Armstrong, A., Newman, C., Alakhov, V., Pietrzynski, G., Brewer, J., Campbell, S., Corrie, P., Rowinsky, E. K., & Ranson, M. (2011) · Investigational New Drugs · doi:10.1007/s10637-010-9399-1 · Cited by 303
White, M. H., Bowden, R. A., Sandler, E. S., Graham, M. L., Noskin, G. A., Wingard, J. R., Goldman, M., van Burik, J., McCabe, A., Lin, J., et al. (1998) · Clinical Infectious Diseases · doi:10.1086/514672 · Cited by 303
Hamaguchi, T., Kato, K., Yasui, H., Morizane, C., Ikeda, M., Ueno, H., Muro, K., Yamada, Y., Okusaka, T., Shirao, K., et al. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603855 · Cited by 290
Phase I Study of a Systemically Delivered p53 Nanoparticle in Advanced Solid Tumors
Senzer, N., Nemunaitis, J., Nemunaitis, D., Bedell, C., Edelman, G., Barve, M., Nunan, R., Pirollo, K. F., Rait, A., & Chang, E. H. (2013) · Molecular Therapy · doi:10.1038/mt.2013.32 · Cited by 236
Weiss, G. J., Chao, J., Neidhart, J. D., Ramanathan, R. K., Bassett, D., Neidhart, J. A., Choi, C. H. J., Chow, W., Chung, V., Forman, S. J., et al. (2013) · Investigational New Drugs · doi:10.1007/s10637-012-9921-8 · Cited by 230
Phase II studies of nebulised Arikace in CF patients with Pseudomonas aeruginosa infection
Clancy, J. P., Dupont, L., Konstan, M. W., Billings, J., Fustik, S., Goss, C. H., Lymp, J., Minic, P., Quittner, A. L., Rubenstein, R. C., et al. (2013) · Thorax · doi:10.1136/thoraxjnl-2012-202230 · Cited by 222
Langer, C. J., O’Byrne, K. J., Socinski, M. A., Mikhailov, S. M., Leśniewski-Kmak, K., Smakal, M., Ciuleanu, T. E., Orlov, S. V., Dediu, M., Heigener, D., et al. (2008) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181753b4b · Cited by 202
Ahn, H. K., Jung, M., Sym, S. J., Shin, D. B., Kang, S. M., Kyung, S. Y., Park, J.-W., Jeong, S. H., & Cho, E. K. (2014) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-014-2498-5 · Cited by 183
Dendrimers as tunable vectors of drug delivery systems and biomedical and ocular applications
Chaniotakis, N., Thermos, K., & Kalomiraki, M. (2015) · International Journal of Nanomedicine · doi:10.2147/ijn.s93069 · Cited by 179
Cortes, J. E., Goldberg, S. L., Feldman, E. J., Rizzeri, D. A., Hogge, D. E., Larson, M., Pigneux, A., Recher, C., Schiller, G., Warzocha, K., et al. (2015) · Cancer · doi:10.1002/cncr.28974 · Cited by 175
Price, C. F., Tyssen, D., Sonza, S., Davie, A., Evans, S., Lewis, G. R., Xia, S., Spelman, T., Hodsman, P., Moench, T. R., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0024095 · Cited by 173
Paz-Ares, L., Ross, H., O'Brien, M., Riviere, A., Gatzemeier, U., Von Pawel, J., Kaukel, E., Freitag, L., Digel, W., Bischoff, H., et al. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604372 · Cited by 171
Suspected anaphylactic reaction to Cremophor EL.
Dye, D., & Watkins, J. (1980) · BMJ · doi:10.1136/bmj.280.6228.1353 · Cited by 169
Ko, A. H., Tempero, M. A., Shan, Y.-S., Su, W.-C., Lin, Y.-L., Dito, E., Ong, A., Wang, Y.-W., Yeh, C. G., & Chen, L.-T. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.408 · Cited by 160
Cantón, R., Cobos, N., de Gracia, J., Baquero, F., Honorato, J., Gärtner, S., Alvarez, A., Salcedo, A., Oliver, A., & Garcia-Quetglas, E. (2005) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2005.01217.x · Cited by 158
Hamaguchi, T., Doi, T., Nakajima, T. E., Kato, K., Yamada, Y., Shimada, Y., Fuse, N., Ohtsu, A., Matsumoto, S.-I., Takanashi, M., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0387 · Cited by 145
O'Brien, M. E. R., Socinski, M. A., Popovich, A. Y., Bondarenko, I., Tomova, A., ̆ı, B. T. B., Hotko, Y., Ganul, V. L., Kostinsky, I. Y., Eisenfeld, A. J., et al. (2008) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31817c6b68 · Cited by 125
Nanocarriers in Gene Therapy: A Review
Xu, H., Li, Z., & Jin, S. (2014) · Journal of Biomedical Nanotechnology · doi:10.1166/jbn.2014.2044 · Cited by 120
Wang, H.-L., Wang, S.-S., Song, W.-H., Pan, Y., Yu, H.-P., Si, T.-G., Liu, Y., Cui, X.-N., & Guo, Z. (2015) · PLoS ONE · doi:10.1371/journal.pone.0125924 · Cited by 115
Tsukioka, Y., Matsumura, Y., Hamaguchi, T., 小池浩代, Moriyasu, F., & Kakizoe, T. (2002) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.2002.tb01217.x · Cited by 114
Phase II study of liposomal cisplatin (SPI-77) in platinum-sensitive recurrences of ovarian cancer.
Seetharamu, N., Kim, E., Höchster, H. S., Martin, F., & Muggia, F. M. (2010) · PubMed · Cited by 107
Safety, Tolerability, and Pharmacokinetics of SPL7013 Gel (VivaGel®): A Dose Ranging, Phase I Study
O'Loughlin, J. A., Millwood, I. Y., McDonald, H. M., et al. (2010) · Sexually Transmitted Diseases · doi:10.1097/olq.0b013e3181bc0aac · Cited by 97
Gabizon, A., Tzemach, D., Horowitz, A. T., Shmeeda, H., Yeh, J., & Zalipsky, S. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1547 · Cited by 97
Negishi, T., Koizumi, F., Uchino, H., Kuroda, J.-I., Kawaguchi, T., Naito, S., & Matsumura, Y. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603311 · Cited by 92
Hepatic-Directed Vesicle Insulin: A Review of Formulation Development and Preclinical Evaluation
Geho, W. B., Geho, H. C., Lau, J. R., & Gana, T. J. (2009) · Journal of Diabetes Science and Technology · doi:10.1177/193229680900300627 · Cited by 92
Paclitaxel Poliglumex (PPX-Xyotax) and Concurrent Radiation for Esophageal and Gastric Cancer
DiPetrillo, T. A., Milas, L., Evans, D. L., Akerman, P., Ng, T., Miner, T., Cruff, D., Chauhan, B., Iannitti, D. A., Harrington, D. T., et al. (2006) · American Journal of Clinical Oncology · doi:10.1097/01.coc.0000224494.07907.4e · Cited by 74
Cohen, C. R., Brown, J., Moscicki, A., Bukusi, E. A., Paull, J. R., Price, C. F., & SHIBOSKI, S. C. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016258 · Cited by 74
Ueno, T., Endo, K., Hori, K., Ozaki, N., Tsuji, A., Kondo, S., Wakisaka, N., Murono, S., Kataoka, K., Kato, Y., et al. (2014) · International Journal of Nanomedicine · doi:10.2147/ijn.s60564 · Cited by 69
Gaur, S., Chen, L., Yen, T., Wang, Y., Zhou, B., Davis, M. E., & Yen, Y. (2011) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2011.09.007 · Cited by 68
Gabizón, A., Amitay, Y., Tzemach, D., Gorin, J., Shmeeda, H., & Zalipsky, S. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.11.019 · Cited by 66
Sabbatini, P. J., Sill, M. W., O’Malley, D. M., Adler, L. M., & Secord, A. A. (2008) · Gynecologic Oncology · doi:10.1016/j.ygyno.2008.07.049 · Cited by 60
PSMA Ligand Conjugated PCL-PEG Polymeric Micelles Targeted to Prostate Cancer Cells
Jin, J., Sui, B., Gou, J., Liu, J., Tang, X., Xu, H., Zhang, Y. X., & Jin, X. (2014) · PLoS ONE · doi:10.1371/journal.pone.0112200 · Cited by 58
Numbenjapon, T., Wang, J., Colcher, D. M., Schluep, T., Davis, M. E., Duringer, J., Kretzner, L., Yen, Y., Forman, S. J., & Raubitschek, A. A. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2619 · Cited by 52
Infante, J. R., Keedy, V. L., Jones, S. F., Zamboni, W. C., Chan, E. W., Bendell, J. C., Lee, W., Wu, H., Ikeda, S., Kodaira, H., et al. (2012) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-012-1960-5 · Cited by 49
Verschraegen, C. F., Skubitz, K. M., DAUD, A. I., Kudelka, A. P., Rabinowitz, I., Allievi, C., Eisenfeld, A. J., Singer, J. W., & Oldham, F. B. (2008) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-008-0813-8 · Cited by 46
Geho, W. B., Rosenberg, L. N., Schwartz, S. L., Lau, J. R., & Gana, T. J. (2014) · Journal of Diabetes Science and Technology · doi:10.1177/1932296814524871 · Cited by 41
Yamamoto, Y., Hyodo, I., Takigahira, M., Koga, Y., Yasunaga, M., Harada, M., Hayashi, T., Kato, Y., & Matsumura, Y. (2013) · International Journal of Cancer · doi:10.1002/ijc.28651 · Cited by 40
Neoadjuvant Paclitaxel Poliglumex, Cisplatin, and Radiation for Esophageal Cancer
DiPetrillo, T. A., Suntharalingam, M., Ng, T., et al. (2011) · American Journal of Clinical Oncology · doi:10.1097/coc.0b013e318201a126 · Cited by 39
Ortega, A., Farah, S., Tranque, P., Ocaña, A. V., Nam‐Cha, S. H., Beyth, N., Gómez‐Roldán, C., Pérez‐Tanoira, R., Domb, A. J., Pérez‐Martínez, F. C., et al. (2015) · IET Nanobiotechnology · doi:10.1049/iet-nbt.2014.0078 · Cited by 38 · cited 1×
“The highly charged quaternary moiety can disrupt the bacterial membrane and has potent activity against a number of gram positive and negative pathogens.(68) The Hadassah Medical Organization (Jerusalem, Isreal) has incorporated QE-PEI nanoparticles into dental composite and has ongoing phase I/II studies evaluating t…”
BackgroundModeling maternal fetal RSV F vaccine induced antibody transfer in guinea pigs
Glenn, G. M., Fries, L. F., Smith, G., Kpamegan, E. P., Lu, H., Guebre‐Xabier, M., Hickman, S. P., & Flyer, D. C. (2015) · Vaccine · doi:10.1016/j.vaccine.2015.08.039 · Cited by 32
Moura, L. A., Ribeiro, F. V., Aiello, T. B., Duek, E. A. D. R., Sallum, E. A., Nociti, F. H., Casati, M. Z., & Sallum, A. W. (2015) · Journal of Biomaterials Science Polymer Edition · doi:10.1080/09205063.2015.1045249 · Cited by 31
Larson, J. L. (2000) · Toxicological Sciences · doi:10.1093/toxsci/53.2.421 · Cited by 31
Richards, D., Richards, P. D., Bodkin, D., Neubauer, M., & Oldham, F. B. (2005) · Clinical Lung Cancer · doi:10.3816/clc.2005.n.039 · Cited by 28
Morgan, M. A., Darcy, K. M., Rose, P. G., DeGeest, K., Bookman, M. A., Aikins, J. K., Sill, M. W., Mannel, R. S., Allievi, C., & Egorin, M. J. (2008) · Gynecologic Oncology · doi:10.1016/j.ygyno.2008.05.008 · Cited by 23
Gergis, U. S., Roboz, G. J., Shore, T. B., Ritchie, E. K., Mayer, S. A., Wissa, U., McKenna, M., Christos, P. J., Pearse, R. N., Mark, T. M., et al. (2013) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2013.04.013 · Cited by 18
Hentschel, M., Mirtsch, S., Jordan, A., Wust, P., Vogl, T., Semmler, W., Wolf, K. ‐., & FELIX, R. (1997) · International Journal of Hyperthermia · doi:10.3109/02656739709056431 · Cited by 7
Cited by
Engineering precision nanoparticles for drug delivery
Mitchell, M. J., Billingsley, M. M., Haley, R. M., Wechsler, M. E., Peppas, N. A., & Langer, R. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0090-8 · Cited by 7,933
Nano based drug delivery systems: recent developments and future prospects
Patra, J. K., Das, G., Fraceto, L. F., Campos, E. V. R., Rodriguez-Torres, M. D. P., Acosta-Torres, L. S., Diaz-Torres, L. A., Grillo, R., Swamy, M. K., Sharma, S., et al. (2018) · Journal of Nanobiotechnology · doi:10.1186/s12951-018-0392-8 · Cited by 6,684
Nanomaterial-based therapeutics for antibiotic-resistant bacterial infections
Makabenta, J. M. V., Nabawy, A., Li, C.-H., Schmidt-Malan, S., Patel, R., & Rotello, V. M. (2021) · Nature Reviews Microbiology · doi:10.1038/s41579-020-0420-1 · Cited by 1,397
Hua, S., de Matos, M. B. C., Metselaar, J. M., & Storm, G. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00790 · Cited by 1,048
Nano-Strategies to Fight Multidrug Resistant Bacteria—“A Battle of the Titans”
Baptista, P. V., McCusker, M. P., Carvalho, A., Ferreira, D. A., Mohan, N. M., Martins, M., & Fernandes, A. R. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.01441 · Cited by 881
Metadata
- Authors
- Caster, J. M., Patel, A. N., Zhang, T., & Wang, A.
- Venue
- WIREs Nanomedicine and Nanobiotechnology
- Publisher
- Wiley
- Published
- 2016-06-16
- Volume
- 9
- Issue
- 1
- ISSN
- 1939-0041 (ISSN-L)
- 1939-5116
- OpenAlex
- W2425706463
- Cited by
- 380
- References
- 80
- FWCI
- 14.53
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.